Protein Summary
Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity. This gene product appears to function as a negative regulator of the ras signal transduction pathway. Mutations in this gene have been linked to neurofibromatosis type 1, juvenile myelomonocytic leukemia and Watson syndrome. The mRNA for this gene is subject to RNA editing (CGA>UGA->Arg1306Term) resulting in premature translation termination. Alternatively spliced transcript variants encoding different isoforms have also been described for this gene. [provided by RefSeq, Jul 2008]
- ENST00000356175
- ENSP00000348498
- ENSG00000196712
- ENST00000358273
- ENSP00000351015
- ENST00000431387
- ENSP00000412921
- ENST00000487476
- ENSP00000491589
- WSS
- NFNS
- VRNF
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological process | 1 | ||
interacting protein | 0.98 | ||
transcription factor perturbation | 0.94 | ||
protein domain | 0.92 | ||
co-expressed gene | 0.89 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 6541.63 (req: < 5)
Gene RIFs: 449 (req: <= 3)
Antibodies: 430 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 6541.63 (req: >= 5)
Gene RIFs: 449 (req: > 3)
Antibodies: 430 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 73
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0